

Backgrounder Document d'information



Ministry of Research
and Innovation

Le ministère de la Recherche
et de l'Innovation

January 9, 2008

SUPPORT FOR THE MCGUINITY GOVERNMENT'S NEW BIOPHARMACEUTICAL INVESTMENT PROGRAM

"We applaud this move to attract more innovation investment to Ontario. The government's biopharmaceutical investment program is an important step in giving this province a leg up in the global competition for knowledge industry jobs and research. We look forward to continuing to work with the Government of Ontario on this and other initiatives that can help make Ontario and Canada a world leader in biopharmaceutical research and development." **David Ricks, President and General Manager, Eli Lilly Canada Inc.**

"In 2006, global spending on life sciences research and development was almost \$100 billion. Ontario has some of the brightest minds and some of the leading research institutions in the world. By working with the Government of Ontario, we can leverage more investment that will create high-value jobs and fuel research here at home." **Paul Lévesque, President & CEO/Président et chef de la direction, Pfizer Canada Inc.**

"Ontario's new biopharmaceutical investment program is right on the mark. Pharmaceutical investment and business expertise are essential to sustaining and nurturing Ontario's emerging biotechnology industry." **Ilse Treurnicht, CEO, MaRS Discovery District**

"The government's investment program is good news for everyone involved in the research community in Ontario. We look forward to new R&D partnerships between research hospitals like SickKids and pharmaceutical companies that will bring benefits in the form of new therapies and services for our patients." **Dr. Freda Miller, Senior Scientist, The Hospital for Sick Children.**

"Canadian biotechnology companies often sell their technologies at early stages. Investments such as this one by the McGuinty Government should assist companies in attracting the necessary venture capital to take their technologies right through to commercialization in Ontario, which will keep the jobs in Ontario." **Graeme McRae, President & CEO, Bioniche Life Sciences Inc.**

"The CEOs of Rx&D's member companies are ambassadors for Ontario and Canada in the intense global competition to attract research investment and high-value jobs. Our partnership with the Ontario government will help bolster their case." **Dawn Graham, President, Merck Frosst Canada.**

“The creation of this new biopharmaceutical investment program is recognition by the Ontario government that innovation is the engine of our modern economy.” **Philip Blake, President & CEO, Bayer Inc.**

-30-

Contacts:

Perry Blocher
Ministry of Research and Innovation
416-326-7717

Sandra Watts
Minister's Office
416-314-7067

Disponible en français

www.ontario.ca/innovation